New hope for post-transplant bladder bleeding: cidofovir shows promise
NCT ID NCT01295645
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at whether adding the drug cidofovir to usual care helps people who develop painful bladder bleeding from the BK virus after a stem cell transplant. About 27 participants received either cidofovir or standard supportive care. The goal was to see if symptoms improved and virus levels dropped. The study is now complete but results are still being analyzed.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRANSPLANTATION INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A new drug combo may shield kidney transplant patients from a common viral threat
- Could a Double-Dose flu vaccine better protect transplant kids?
- Lung transplant patients may get better flu protection with high-dose vaccine
- Could a double-dose flu vaccine protect vulnerable transplant patients better?